We are live on ! Find out more
RUBY

Rubius Therapeutics, Inc
RUBY

Delisted

RUBY was delisted on the 6th of March, 2023.

Back to rankings

108 hedge funds and large institutions have $863M invested in Rubius Therapeutics, Inc in 2021 Q4 according to their latest regulatory filings, with 18 funds opening new positions, 44 increasing their positions, 27 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

63% more repeat investments, than reductions

Existing positions increased: 44 | Existing positions reduced: 27

29% more first-time investments, than exits

New positions opened: 18 | Existing positions closed: 14

3% more funds holding

Funds holding: 105 → 108 (+3)

0% more funds holding in top 10

Funds holding in top 10: 3 → 3 (0)

0% less call options, than puts

Call options by funds: $614K | Put options by funds: $617K

44% less capital invested

Capital invested by funds: $1.55B → $863M (-$682M)

Holders
108
Holders Change
+3
Holders Change %
+2.86%
% of All Funds
1.66%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
18
Increased
44
Reduced
27
Closed
14
Calls
$614K
Puts
$617K
Net Calls
-$3K
Net Calls Change
-$1.95M

Top Buyers

Rank Fund Capital Flow
1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$12.9M
2
JP Morgan Chase
JP Morgan Chase
New York
+$9.83M
3
Victory Capital Management
Victory Capital Management
Texas
+$8.76M
4
Baillie Gifford & Co
Baillie Gifford & Co
United Kingdom
+$3.29M
5
Morgan Stanley
Morgan Stanley
New York
+$1.99M

Top Sellers

Rank Fund Capital Flow
1
AG
Artal Group
Luxembourg
-$6.3M
2
State Street
State Street
Massachusetts
-$2.59M
3
PP
PDT Partners
New York
-$1.18M
4
Tudor Investment Corp
Tudor Investment Corp
Connecticut
-$824K
5
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans
Minnesota
-$730K
Name Holding Trade Value Shares
Change 		Change in
Stake
N
26
Nuveen
North Carolina
$1.69M +$415K +29,924 +21%
Norges Bank
27
Norges Bank
Norway
$1.69M – – –
Bank of New York Mellon
28
Bank of New York Mellon
New York
$1.44M -$587K -42,349 -22%
Citigroup
29
Citigroup
New York
$1.33M +$588K +42,400 +45%
Rafferty Asset Management
30
Rafferty Asset Management
New York
$1.16M +$465K +33,568 +39%
UBS Group
31
UBS Group
Switzerland
$1.03M +$343K +24,734 +30%
D.E. Shaw & Co
32
D.E. Shaw & Co
New York
$890K -$156K -11,278 -11%
Swiss National Bank
33
Swiss National Bank
Switzerland
$861K – – –
Susquehanna International Group
34
Susquehanna International Group
Pennsylvania
$860K +$616K +44,450 +100%
Ameriprise
35
Ameriprise
Minnesota
$798K +$311K +22,453 +37%
State of Wisconsin Investment Board
36
State of Wisconsin Investment Board
Wisconsin
$768K +$215K +15,500 +24%
VIA
37
Vident Investment Advisory
Georgia
$734K +$284K +20,479 +37%
Renaissance Technologies
38
Renaissance Technologies
New York
$687K +$700K +50,454 +246%
TD Asset Management
39
TD Asset Management
Ontario, Canada
$626K +$897K +64,710 New
Bank of America
40
Bank of America
North Carolina
$607K +$295K +21,268 +51%
Citadel Advisors
41
Citadel Advisors
Florida
$589K +$580K +41,794 +219%
AllianceBernstein
42
AllianceBernstein
Tennessee
$581K – – –
California State Teachers Retirement System (CalSTRS)
43
California State Teachers Retirement System (CalSTRS)
California
$577K +$24.5K +1,765 +3%
Wells Fargo
44
Wells Fargo
California
$559K +$143K +10,300 +22%
NFGH
45
Nan Fung Group Holdings
Hong Kong
$550K – – –
Barclays
46
Barclays
United Kingdom
$540K +$493K +35,566 +176%
Millennium Management
47
Millennium Management
New York
$508K +$448K +32,311 +160%
PPA
48
Parametric Portfolio Associates
Washington
$507K -$462K -33,347 -39%
Deutsche Bank
49
Deutsche Bank
Germany
$489K -$14.3K -1,028 -2%
RhumbLine Advisers
50
RhumbLine Advisers
Massachusetts
$465K -$148K -10,662 -18%
1
2
3 4 5

RUBY Hedge Fund Activity: Q4 2021 in Review

108 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Rubius Therapeutics, Inc (RUBY) for Q4 2021, worth a combined $863M — down 44% from $1.55B a quarter earlier.

Buyers outnumbered sellers: 18 funds opened new RUBY positions and 14 closed out — a net gain of 4 holders — while 44 added to existing stakes and 27 trimmed.

The largest buyer was T. Rowe Price Associates, opening a new position worth an estimated $12.9M. The largest seller was Artal Group, cutting an estimated $6.3M.

  • 108 institutional investors held Rubius Therapeutics, Inc (RUBY) as of Q4 2021, up from 105 in Q3 2021.
  • Funds reported $863M of Rubius Therapeutics, Inc stock for Q4 2021, down 44% quarter-over-quarter.
  • 18 funds opened new Rubius Therapeutics, Inc positions in Q4 2021 and 14 closed out, a net change of +4 holders.
  • The largest Rubius Therapeutics, Inc buyer in Q4 2021 was T. Rowe Price Associates, an estimated $12.9M added.
  • The largest Rubius Therapeutics, Inc seller in Q4 2021 was Artal Group, an estimated $6.3M sold.

Based on aggregated 13F filings for Q4 2021.